Precision medicine is not waiting for permission.
The science is moving through blood tests, targeted drugs, molecularly defined trials, AI tools, companion diagnostics and new treatment pathways. But access is being decided somewhere else: in pricing fights, procurement rules, paperwork, supply chains, reimbursement committees and the small print of eligibility.
That is the uncomfortable truth. Personalised medicine does not fail only when the science fails. It fails when the patient gets lost between the signal and the system.
This week’s brief is about the new gatekeepers.
Not only regulators. Not only payers. Not only clinicians. The gatekeepers now include trade politics, diagnostic capacity, administrative rules, medicine supply chains, legal systems and the ability of hospitals to act fast enough when science says: this patient is eligible now.
The last mile is no longer a slogan. It is where the fight is happening.
| This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action. |
Drug pricing is becoming trade policy, and patients are in the middle
The pressure on Germany shows how quickly medicine pricing has moved from health policy into geopolitical negotiation. Pfizer’s CEO warned that proposed German drug pricing rules could put investment at risk, after similar warnings or reversals from Eli Lilly and Boehringer Ingelheim. The message from industry is not subtle: lower prices may come with a bill attached. (Reuters.)
Germany is not just another market. It is Europe’s largest economy, a major pharmaceutical base and one of the key reference points in the European access chain. If Germany tightens prices, other countries watch. If companies delay launches, patients watch. If investment moves elsewhere, politicians watch. Suddenly, the price of a medicine is not only a reimbursement question. It is an industrial strategy question. (Reuters.)
This is the new transatlantic squeeze. The U.S. wants lower medicine prices at home. Europe wants to keep budgets under control. Industry wants higher returns where it can get them. Patients sit in the middle, hearing beautiful words about innovation while wondering whether the medicine will actually arrive, be reimbursed and stay available. (Reuters.)
For IPM, this is exactly where personalised medicine becomes political. A molecularly targeted medicine is not accessible because it exists. It becomes accessible when the price, evidence, pathway, diagnostic test, budget impact and delivery model survive the negotiation.
When pricing becomes a trade weapon, the last mile gets longer.
It is in the blood, but access is still in the system
Liquid biopsy is moving cancer care from waiting for progression to acting on molecular warning signs. In advanced ER-positive, HER2-negative breast cancer, ESR1 testing is now part of treatment access: the FDA approval of vepdegestrant makes eligibility dependent on ESR1 mutation status detected by an FDA-authorised test. No test, no treatment. It does not get clearer than that. (FDA.)
SERENA-6 pushed the logic further. In patients with advanced HR-positive breast cancer whose blood showed an emerging ESR1 mutation, switching endocrine therapy before conventional disease progression reduced the risk of progression or death by 56%. That is not just a drug result. It is a pathway result. You have to test early enough, repeat the test, read the signal and act before the scan tells you the cancer has moved. (AstraZeneca.)
The same story is being written in lung cancer. Edge Health’s evaluation of ctDNA testing in non-small cell lung cancer, commissioned to support an NHS England pilot, showed why liquid biopsy matters for the whole system: faster genomic results, less pressure on tissue pathways and potential efficiency gains when testing is placed early enough in the diagnostic journey. (Edge Health.)
This is where the politics begins. In specialist centres, serial molecular monitoring can become routine. Outside those centres, patients may still wait for tissue, wait for results, wait for referral and wait for the system to notice that the disease has already changed.
ddPCR may offer a faster, cheaper and more decentralised option when the clinical question is focused. NGS remains essential when broader profiling is needed. The policy problem is knowing which test is needed, when, for whom, who pays, and who is accountable when the result comes back too late.
Blood carries the signal. Pathways decide whether it becomes survival.
IPM Latest
The IPM Alliance platform is now live, and this is where the last-mile conversation will continue beyond the newsletter: briefings, policy signals, disease-area work, event updates, stakeholder intelligence and implementation activity across regions. Follow the platform here: IPM Alliance.
We are not building another place to admire innovation from a distance. The point is to track where innovation gets stuck: diagnostics, reimbursement, referral, data, workforce, infrastructure, political will and patient navigation.
You can also follow IPM Alliance on LinkedIn, where we will publish the sharper updates, event moments and signals that do not wait for a full brief.
The science is moving daily. The system has to be watched daily too.
What’s moving
Pancreatic cancer gets a jolt, but keep your seatbelt on
Tango Therapeutics reported early Phase 1/2 data in MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma, with vopimetostat plus daraxonrasib showing a 92% objective response rate in 12 evaluable patients and a six-month progression-free survival rate of 90%. The signal is striking. It is also early, small and not yet the same thing as a standard of care. That distinction matters. (Tango Therapeutics.)
Still, this is exactly the kind of moment health systems need to watch. If the signal holds in larger studies, access will depend on whether systems can identify MTAP-deleted, RAS-mutant patients quickly enough, refer them to the right trial or treatment pathway, and avoid leaving precision oncology trapped inside a few elite centres.
The market heard the signal too. Standard BioTools and Treeline Biosciences announced a merger to create a precision medicines company with more than $900 million expected at closing and multiple clinical readouts planned from 2027. Capital is moving toward molecularly defined medicine. The question is whether health systems are moving toward molecularly ready care. (Standard BioTools.)
The pipeline is accelerating. The pathway cannot be an afterthought.
What are the obstacles?
No stock, no access
Europe’s Critical Medicines Act is a reminder that access does not only fail at the glamorous end of innovation. It can fail much earlier, when the medicine cabinet is empty. The EU provisional agreement aims to reduce shortages, diversify supply chains, support strategic manufacturing projects and strengthen the availability of critical medicines. (Source: EMA; European Commission.)
This matters for personalised medicine because high-tech care still sits on ordinary system reliability. A biomarker-driven pathway means little if supportive medicines, hospital drugs, antibiotics, anaesthetics, infusion capacity or chronic disease medicines are not available when needed.
The politics of access is widening. It is not only about breakthrough therapies, regulatory approval and reimbursement. It is also about whether health systems can keep the basics moving while the science gets more complex.
Patient Access
Access can be lost in the paperwork
The Medicaid work-rule debate in the United States shows a different side of personalised medicine. A patient can have the right diagnosis, the right doctor and the right treatment pathway, and still lose care because the system asks whether they can prove they are “medically frail” in the correct way. (KFF.)
The American Cancer Society Cancer Action Network warned that recent restrictions could make it harder for medically frail people, including people with cancer, to be exempt from Medicaid work requirements. CMS guidance sets out the implementation pathway for work requirements, exemptions and verification. The politics is about work. The patient reality is about paperwork, documentation and whether coverage disappears when care is most needed. (ACS CAN; CMS.)
For IPM, the lesson is blunt. Eligibility is not only molecular. It is administrative. If a patient has to repeatedly prove illness, chase forms, secure documentation and navigate exemptions, access can fail before treatment even begins.
A health system that makes illness harder to prove can make treatment harder to reach.
From Pipeline to Pathway
China is not just eating lunch. It is changing the menu.
China is no longer only the low-cost supplier in the pharmaceutical system. It is becoming a pricing and innovation challenge that Europe and the U.S. cannot ignore. Greater China licensing deal values reached $137.7 billion in 2025, and analysts expect further momentum in 2026. Pfizer’s recent collaboration with Innovent alone could be worth up to $10.5 billion across 12 early-stage oncology programmes. (Reuters; Reuters.)
That does not mean the world should simply cheer or panic. It means the old map is outdated. Innovation is moving, licensing is moving, pricing pressure is moving, and Western companies are increasingly looking east for assets while Western politicians worry about dependence.
The access question is uncomfortable but unavoidable. Are health systems protecting patients, or protecting old business models? Patients need both affordability and innovation. The politics of drug pricing will decide whether they get either.
Public fight, private stakes
Trump fills the global health seat. Ebola is already moving.
The public fight is in Washington. The private stakes are in Central Africa. The Trump administration has nominated Johnny Figueroa as U.S. Ambassador-at-Large for Global Health Security and Diplomacy, and coordinator of U.S. activities to combat HIV/AIDS globally.The Senate still has to confirm him, but after nearly a year and a half without a nominee, one of the most important global health seats finally has a name attached. (White House; Devex.)
The timing is brutal. Ebola is spreading in the Democratic Republic of Congo and Uganda, with the response complicated by insecurity, late detection, weak logistics and the absence of an approved vaccine for this Ebola species. WHO has launched a major response plan, but the outbreak is already testing whether global health diplomacy can still move at outbreak speed. (CDC; Reuters.)
For IPM, the lesson is familiar. Science is not enough if leadership arrives late, money moves slowly, diagnostics miss the signal, and communities do not trust the system.
The nomination is welcome. The hearing matters. The outbreak will not wait.
When access runs through a courtroom
Latin America shows another face of the global drug-pricing fight. In Europe, the argument is often about launch delays and budget pressure. In the U.S., it is about lowering prices. In parts of Latin America, the pathway can become litigation: patients using courts to obtain medicines that the health system has not made predictably available. (Health Policy Watch.)
Reported health access litigation rose by 130% in Brazil and 119% in Colombia over a decade. That is not a functioning access pathway. That is a system telling patients: bring a lawyer. (Health Policy Watch; Journal of Law, Medicine & Ethics.)
This matters for IPM because personalised medicine will not be globally credible if access depends on legal literacy, personal networks or the ability to fight case by case. The promise is targeted care. The reality, too often, is targeted access for those who can navigate the system.
A medicine is not truly accessible when the pathway runs through a courtroom.
The June watchlist
June is not done. The second half of the month brings decisions and meetings that could shape the next access fights.
| 19 June, EU & online: |
| European Commission HTA webinar for high-risk medical devices and IVD developers. |
| 22 June, UK: |
| The MHRA consultation on gene therapy regulation closes. (MHRA.) |
| 22-25 June, Amsterdam: |
| EMA committee for medicinal products for human use plenary. |
| 22-25 June, San Diego, US: |
| BIO International Convention gathers the biotech ecosystem. (BIO.) |
| 24-27 June, Philadelphia, US: |
| AACR’s malignant lymphoma meeting puts blood cancers back in the precision medicine spotlight. (AACR.) |
Follow the last-mile conversation!
IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.
We want to hear from you
When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?
Know someone who should be reading this?
IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.
International Alliance for Personalised Medicine
Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium
This email was sent to jayasinghtec29@gmail.com. You are receiving this email because you are part of the IPM Alliance network or have engaged with our activities, briefings, events, or policy work.
